Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems

Abstract Cancer remains the second leading cause of death globally, driving the need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% of recently approved anticancer drugs. Despite their potential, early clinical trials faced...

Descripción completa

Detalles Bibliográficos

Autores principales:	Matteo Perra, Ines Castangia, Matteo Aroffu, Federica Fulgheri, Rita Abi-Rached, Maria Letizia Manca, Hernán Cortés, María Luisa Del Prado-Audelo, Carla Nomura-Contreras, Alejandra Romero-Montero, Dietrich Büsselberg, Gerardo Leyva-Gómez, Javad Sharifi-Rad, Daniela Calina
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Springer 2025-01-01
Colección:	Discover Oncology
Materias:	Maytansine Maytansinoid-based therapies Antibody-maytansinoid conjugates Natural compounds Anticancer studies Microtubules polymerization inhibitors
Acceso en línea:	https://doi.org/10.1007/s12672-025-01820-z
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!